Patents by Inventor Reid P. Bissonnette

Reid P. Bissonnette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
    Publication number: 20230151099
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Application
    Filed: November 23, 2022
    Publication date: May 18, 2023
    Inventors: Reid P. BISSONNETTE, Alain ROLLAND, Mireille GILLINGS
  • Combination therapies of HDAC inhibitors and PD-L1 inhibitors
    Patent number: 11535670
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: December 27, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS
    Publication number: 20220110924
    Abstract: Provided herein is a therapy comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.
    Type: Application
    Filed: August 24, 2021
    Publication date: April 14, 2022
    Inventors: Reid P. BISSONNETTE, Rosemary M. CESARIO, Robert GOODENOW, Farbod SHOJAEI, Mireille GILLINGS
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
    Publication number: 20200181267
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Application
    Filed: August 14, 2019
    Publication date: June 11, 2020
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20200172621
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Application
    Filed: August 14, 2019
    Publication date: June 4, 2020
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Combination therapies of HDAC inhibitors and PD-L1 inhibitors
    Patent number: 10385131
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 20, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Combination therapies of HDAC inhibitors and PD-1 inhibitors
    Patent number: 10385130
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 20, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Combination therapies of HDAC inhibitors and PD-1 inhibitors
    Patent number: 10287353
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 14, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS
    Publication number: 20190046513
    Abstract: Provided herein are combinations that include a histone deacetylase inhibitor and tubulin inhibitor such as eribulin or a pharmaceutically acceptable salt thereof that are useful for treating cancer, including reducing cancer metastasis.
    Type: Application
    Filed: August 14, 2017
    Publication date: February 14, 2019
    Inventors: Reid P. Bissonnette, Alain Rolland, Robert Goodenow, Mireille Gillings
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20180355042
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20170327582
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 16, 2017
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
    Publication number: 20170327583
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 16, 2017
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS
    Publication number: 20140243324
    Abstract: The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin.
    Type: Application
    Filed: November 17, 2011
    Publication date: August 28, 2014
    Applicant: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Reid P. Bissonnette, Andrew R. Hudson, Keith B. Marschke, Deepa Rungta, Lin Zhi